Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) plus bevacizumab (BEV): Results of a subanalysis of the randomized phase III CECOG TURANDOT trial

被引：0

作者：

Christoph, Zielinski C. ^{[1
]}

Istvan, Lang

Semir, Beslija

Zsuzsanna, Kahan ^{[2
]}

Inbar, Moshe J. ^{[3
]}

Salomon, Stemmer M. ^{[4
]}

Rodica, Anghel ^{[5
]}

Damir, Vrbanec ^{[6
]}

Diethelm, Messinger ^{[7
]}

Thomas, Brodowicz ^{[1
]}

机构：

[1] Med Univ Vienna, Vienna, Austria

[2] Univ Szeged, Szeged, Hungary

[3] Tel Aviv Sourasky Med Ctr, Tel Hashomer, Israel

[4] Rabin Med Ctr, Petah Tiqwa, Israel

[5] Univ Med & Pharm Buchurest, Bucharest, Romania

[6] Univ Hosp Rebro, Zagreb, Croatia

[7] IST GmbH, Mannheim, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3-06-10

引用

页数：2